NEW YORK – Early-stage biotechnology Modular Bioscience said on Tuesday that it has signed a definitive agreement with the University of Illinois at Urbana-Champaign for an exclusive global patent license to a novel artificial restriction enzyme (ARE) platform developed by researchers at the university.